Cite
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial
MLA
Kapp-Schwoerer, Silke, et al. “Impact of Gemtuzumab Ozogamicin on MRD and Relapse Risk in Patients with NPM1-Mutated AML: Results from the AMLSG 09-09 Trial.” Blood, vol. 136, no. 26, Dec. 2020, pp. 3041–50. EBSCOhost, https://doi.org/10.1182/blood.2020005998.
APA
Kapp-Schwoerer, S., Weber, D., Corbacioglu, A., Gaidzik, V. I., Paschka, P., Krönke, J., Theis, F., Rücker, F. G., Teleanu, M.-V., Panina, E., Jahn, N., Herzig, J., Kubanek, L., Schrade, A., Göhring, G., Fiedler, W., Kindler, T., Schroeder, T., Mayer, K. T., … Döhner, K. (2020). Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood, 136(26), 3041–3050. https://doi.org/10.1182/blood.2020005998
Chicago
Kapp-Schwoerer, Silke, Daniela Weber, Andrea Corbacioglu, Verena I. Gaidzik, Peter Paschka, Jan Krönke, Frauke Theis, et al. 2020. “Impact of Gemtuzumab Ozogamicin on MRD and Relapse Risk in Patients with NPM1-Mutated AML: Results from the AMLSG 09-09 Trial.” Blood 136 (26): 3041–50. doi:10.1182/blood.2020005998.